Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Phase 2 Terminated 17 enrolled Washington University School of Medicine Secura Bio, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that duvelisib maintenance after autologous stem cell transplant in patients with T-cell lymphomas will be safe and well tolerated, and will improve progression free survival.

Timeline

Start: 2020-07-23
Primary completion: 2026-04-22
Completion: 2026-04-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duvelisib	Small molecule	25 mg	Oral

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Summary

Timeline

Drugs

Indications